Organon & Co. (OGN) Aktienanalyse

Unternehmensübersicht

Organon & Co. operates as a specialized manufacturer within the healthcare sector, focusing on the development and delivery of women's health solutions through prescription therapies and medical devices across a vast global footprint including the United States, Europe, Canada, Japan, China, Latin America, the Middle East, Russia, Africa, and other international markets. The company is categorized under the industry of Drug Manufacturers - General, which positions it as a key player in the pharmaceutical supply chain dedicated to specific therapeutic areas rather than broad-spectrum treatments. Currently, the organization employs approximately 10,000 individuals to support its extensive operational network and research capabilities. With a market capitalization of $1.52B and annual revenue reaching $6.22B, the company demonstrates a significant scale that places it among the substantial entities in the women's health pharmaceutical segment. These valuation and revenue figures indicate that Organon maintains a substantial market presence, reflecting the high capital requirements and broad distribution networks necessary for a global drug manufacturer.

Finanzielle Gesundheit

The company reported total revenue of $6.22B over the trailing twelve months, with net income standing at $187.00M and EBITDA totaling $1.65B. The substantial gap between the $6.22B in revenue and the $187.00M in net income reveals a cost structure where significant expenses, including cost of goods sold, research and development, and administrative costs, consume approximately 97% of gross revenue before arriving at the bottom line. Despite the large revenue base, the generation of $1.65B in EBITDA highlights the operational profitability before interest and tax obligations, providing a clear view of core business earnings power. The free cash flow stands at $190.12M, which indicates a positive ability to generate cash from operations after capital expenditures, offering the company financial flexibility for debt servicing or potential strategic investments. The balance sheet shows a cash position of $574.00M against total debt of $8.80B, resulting in a debt-to-equity ratio of 1170.21, which suggests a highly leveraged capital structure rather than a conservative one. Liquidity for short-term obligations is supported by a current ratio of 1.82, indicating that current assets are more than double current liabilities and providing a buffer against immediate financial pressures. Efficiency metrics show a return on equity of 30.6% and a return on assets of 6.2%, revealing that while the company generates high returns on shareholder equity, the broader asset base yields a lower percentage return, likely due to the heavy debt load impacting the denominator in the ROA calculation.

Bewertungsanalyse

Valuation metrics for Organon & Co. show a trailing P/E ratio of 8.11 and a forward P/E of 1.57, where the significant difference between these two figures implies that the market expects earnings to expand dramatically in the future to justify the current low multiple or that current earnings are temporarily depressed. The price-to-book ratio is listed at 2.02, indicating that the stock trades at a premium of roughly two times its book value, suggesting investors are willing to pay more for the company's tangible assets than their accounting value. Alternative valuation measures such as a price-to-sales ratio of 0.24 and an EV/EBITDA of 5.89 suggest that the market values the company based on very low multiples relative to its sales volume and enterprise earnings. Regarding price action, the stock has a 52-week high of $15.85 and a 52-week low of $5.83, meaning the current share price sits within a wide trading range influenced by recent market volatility. The beta value is 0.57, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it moves less aggressively than the S&P 500 during periods of market fluctuation.

Growth & Income

Revenue growth year-over-year is recorded at -5.3%, while earnings growth is marked as N/A, indicating that there are no reported comparable earnings figures for a year-over-year growth calculation in the available data. The negative revenue growth rate suggests a contraction in top-line sales, whereas the absence of earnings growth data prevents a direct comparison between revenue and earnings trajectories for the current period. The company pays a dividend with a yield of 1.4% and maintains a payout ratio of 47.2%, which suggests that the dividend payment consumes less than half of the reported earnings and may be sustainable given the current net income levels. The overall growth and income profile for Organon & Co. is characterized by a period of revenue contraction alongside a modest dividend yield, reflecting a mature phase of the business cycle where capital allocation focuses on maintaining payouts rather than driving rapid top-line expansion.